Ascendiant Capital Initiates Aldeyra Therapeutics With Buy
Analysts at Ascendiant Capital initiated coverage on Aldeyra Therapeutics (NASDAQ: ALDX) with a Buy rating.
The target price for Aldeyra Therapeutics is set to $16.
Aldeyra Therapeutics' shares fell 1.09% to close at $7.26 yesterday.
Latest Ratings for ALDX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2021 | Citigroup | Maintains | Buy | |
| Dec 2021 | SVB Leerink | Maintains | Outperform | |
| Mar 2021 | SVB Leerink | Initiates Coverage On | Outperform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Ascendiant CapitalInitiation Analyst Ratings
